AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39141577
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg every 2 weeks (dose-expansion cohort)
Trial: 39141622
Drug: Sleep Restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep Restriction Therapy (SRT) delivered over 4 weekly sessions comprising two face-to-face meetings and two telephone calls.
Trial: 39141622
Drug: Sleep Hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep Hygiene Education (SHE) administered in booklet form.
Trial: 39141987
Drug: soluble mRNA
RxNorm normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soluble mRNA (100 μg/animal)
Trial: 39141987
Drug: C-terminal transmembrane
RxNorm normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C-terminal transmembrane mRNA (100 μg/animal)
Trial: 39141987
Drug: protein vaccine
RxNorm normalized name: SARS-CoV-2 rS protein vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: protein vaccine (400 μg/animal)
Trial: 39141987
Drug: non-translatable RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-translatable RNA control (100 μg/animal)
Trial: 39142110
Drug: Rigorous fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigorous fluid management using monitoring of ECW ratio by bioelectrical impedance analysis (BIA) with bolus infusion of crystalloid fluid for dehydrated patients and diuretics for overhydrated patients.
Trial: 39142110
Drug: Traditional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional fluid treatment without BIA monitoring.
Trial: 39142511
Drug: ENDS containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENDS containing 0 mg/ml liquid nicotine
Trial: 39142511
Drug: ENDS containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENDS containing 8 mg/ml liquid nicotine
Trial: 39142511
Drug: ENDS containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENDS containing 36 mg/ml liquid nicotine
Trial: 39142680
Drug: Upfront dose-reduced
RxNorm normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront dose-reduced chemotherapy (25% reduction)
Trial: 39142680
Drug: Full-dose chemotherapy
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose chemotherapy (fluoropyrimidine plus oxaliplatin)
Trial: 39142680
Drug: Fluoropyrimidine monotherapy
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluoropyrimidine monotherapy (full-dose)
Trial: 39142680
Drug: Dose-reduced chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduced chemotherapy (25% reduction)
Trial: 39142718
Drug: Davoceticept (ALPN-202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Davoceticept (ALPN-202) in combination with pembrolizumab (anti-PD-1)
Trial: 39142723
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonists (GLP-1 RAs)
Trial: 39142926
Drug: Upadacitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib (oral Janus kinase inhibitor)
Trial: 39143444
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Intervention (CBI) with walking component; participants categorized as 'sedentary' (≤ 4999 daily steps) or 'not sedentary' (≥ 5000 daily steps)
Trial: 39144362
Drug: Neoadjuvant immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunochemotherapy with paclitaxel (albumin-bound) (260 mg/m2) and short-course radiotherapy
Trial: 39144362
Drug: Neoadjuvant immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunochemotherapy with paclitaxel (albumin-bound) (260 mg/m2)
Trial: 39145150
Drug: Mixed-frequency TENS
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-frequency TENS (2 Hz/80 Hz) administered using specially designed pants
Trial: 39145700
Drug: Potential disease-modifying
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential disease-modifying therapy for LMNA-related DCM (details not specified)
Trial: 39145962
Drug: Lazertinib, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib, 240 mg, once daily
Trial: 39145961
Drug: POC salivary
RxNorm normalized name: Bis(POC)PMPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POC salivary oral rinse test
Trial: 39146178
Drug: Oligofructose-enriched inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oligofructose-enriched inulin (OEI) prebiotic (4 g, 3 times a day)
Trial: 39146178
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 g of maltodextrin, 3 times a day)
Trial: 39146397
Drug: Glucagon receptor
RxNorm normalized name: Glucagon receptor site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon receptor blockade
Trial: 39146562
Drug: Sleep lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep lotion (0.24 ± 0.01% melatonin)
Trial: 39146562
Drug: Sleep lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep lotion
Trial: 39146801
Drug: Antibiotics administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics administered before skin incision
Trial: 39146801
Drug: Antibiotics administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics administered after umbilical cord clamping
Trial: 39146944
Drug: High-dose hyperfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hyperfractionated radiotherapy (54 Gy in 30 fractions)
Trial: 39146944
Drug: Standard-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose radiotherapy (45 Gy in 30 fractions)
Trial: 39146951
Drug: Adjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant pembrolizumab (200 mg IV every 3 weeks for up to 18 doses)
Trial: 39147194
Drug: Topical rSm29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rSm29 (10 µg) plus Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Trial: 39147194
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Trial: 39147194
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo plus Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Trial: 39148102
Drug: Carriers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carriers of deleterious DPYD variants (c.1670C>T, c.1913T>C, c.1925T>C, c.506delC, c.731A>C, c.1740+1G>T, c.763-2A>G)
Trial: 39148107
Drug: Sirolimus 1
RxNorm normalized name: sirolimus 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 1 mg/m²/day with dose adjustments during a two-week titration period to maintain trough blood concentrations between 5 and 10 ng/ml (maximum dose 2 mg)
Trial: 39148128
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous magnesium sulphate administration
Trial: 39148307
Drug: Curcuminoids (Meriva)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (Meriva) 500 mg po bid for 180 days
Trial: 39148430
Drug: MBL949 (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBL949 (0.03 to 20 mg, single ascending dose)
Trial: 39148430
Drug: MBL949 (biweekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBL949 (biweekly dosing for 14 weeks)
Trial: 39148905
Drug: Erlotinib in
RxNorm normalized name: Product containing erlotinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib in combination with palliative thoracic radiotherapy (RT)
Trial: 39148906
Drug: PIPAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC with cisplatin 10.5 mg/m²
Trial: 39148964
Drug: Topical microencapsulated
RxNorm normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical microencapsulated benzoyl peroxide (E-BPO) for eight weeks
Trial: 39148964
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream for eight weeks
Trial: 39148964
Drug: Topical microencapsulated
RxNorm normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical microencapsulated benzoyl peroxide (E-BPO) for four weeks after vehicle cream
Trial: 39148964
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream for four weeks after E-BPO
Trial: 39149474
Drug: Cabozantinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (12 weeks treatment)
Trial: 39149709
Drug: Subretinal injection
RxNorm normalized name: LUXTURNA Suspension for Subretinal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal injection of cord blood platelet-rich plasma (CB-PRP)
Trial: 39149709
Drug: Control (fellow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (fellow eye without treatment)
Trial: 39150490
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) monotherapy for 52 weeks
Trial: 39150711
Drug: Suvorexant (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (15 mg) taken at bedtime for up to 7 days
Trial: 39151165
Drug: Novel module-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel module-based psychological treatment based on cognitive behavioral therapy and family therapy
Trial: 39151419
Drug: Abiraterone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone treatment
Trial: 39151421
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (up to 4 cycles of neoadjuvant chemotherapy followed by 3 cycles of adjuvant intravenous carboplatin/weekly paclitaxel/pembrolizumab, and maintenance pembrolizumab until progression or toxicity, maximum 20 cycles)
Trial: 39151421
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (specifically for patients with PD-L1 combined positive score (CPS) ≥10)
Trial: 39151421
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (specifically for patients with PD-L1 CPS <10)
Trial: 39151436
Drug: Fluorescence-guided bowel
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescence-guided bowel anastomosis (FGBA) with 5 mg of ICG by 2 mL intravenous bolus.
Trial: 39151647
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy based on co-formulated darunavir/ritonavir (800/100 mg) plus lamivudine (300 mg)
Trial: 39151647
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with darunavir/ritonavir plus tenofovir/emtricitabine (300/200 mg) or tenofovir/lamivudine (300/300 mg)
Trial: 39152028
Drug: Low-dose intra-erythrocyte
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intra-erythrocyte dexamethasone sodium phosphate (approximately 5-10 mg)
Trial: 39152028
Drug: High-dose intra-erythrocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intra-erythrocyte dexamethasone sodium phosphate (approximately 14-22 mg)
Trial: 39152028
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (low-dose, high-dose, placebo)
Trial: 39152408
Drug: Group-based antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based antenatal care (G-ANC)
Trial: 39152477
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DM and coronary microvascular dysfunction (CMD)
Trial: 39152477
Drug: DM and
RxNorm normalized name: Mucus Relief DM and Overnight Cold and Flu KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DM and CMD combination
Trial: 39153060
Drug: Guselkumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab treatment (interleukin-23p19 subunit inhibitor)
Trial: 39153779
Drug: rfhSP-D (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rfhSP-D (1 mg/kg, 2 mg/kg, or 4 mg/kg)
Trial: 39153779
Drug: Routine surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine surfactant replacement therapy
Trial: 39153816
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein group (2.0 g/kg per day)
Trial: 39153816
Drug: Standard protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protein group (1.3 g/kg per day)
Trial: 39153818
Drug: Emodepside (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside (30 mg total, six 5 mg tablets)
Trial: 39153818
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg, one tablet)
Trial: 39153911
Drug: ON-SXB (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ON-SXB (sodium oxybate) 9 g at week 13
Trial: 39154316
Drug: Ketamine 1
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1 mg/kg bolus
Trial: 39154316
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 mcg/kg bolus
Trial: 39155700
Drug: HRS-1780 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-1780 (5, 10, 20, 40, 60, and 80 mg)
Trial: 39155700
Drug: HRS-1780 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-1780 (10, 20, and 40 mg) once daily for 7 days
Trial: 39155737
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks for up to 96 weeks
Trial: 39156699
Drug: Fully-automated module
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully-automated module for radiolabeling; pH of 3.6 and precursor dose of 30 μg were used.
Trial: 39157776
Drug: Mindfulness intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness intervention (6-weekly 1.5-hour sessions remotely delivered)
Trial: 39158071
Drug: Daratumumab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in B-cell ALL
Trial: 39158071
Drug: Daratumumab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in childhood T-cell ALL
Trial: 39158071
Drug: Daratumumab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in young adult T-cell ALL
Trial: 39158071
Drug: Daratumumab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in T-cell LL
Trial: 39158295
Drug: Topical terbinafine
RxNorm normalized name: terbinafine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical terbinafine hydrochloride 10% solution (MOB015B)
Trial: 39158584
Drug: mRNA-1273 booster
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 booster dose (10 µg for 6 months-5 years; 25 µg for 6-11 years)
Trial: 39158584
Drug: mRNA-1273 booster
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 booster dose
Trial: 39158589
Drug: Drug-coated balloons
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-coated balloons (Passeo-18 lux DCBs)
Trial: 39158670
Drug: Facilitated subcutaneous
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated subcutaneous immunoglobulin (fSCIG) 10%
Trial: 39158833
Drug: Recombinant porcine
RxNorm normalized name: antihemophilic factor VIII, recombinant porcine sequence 500 (+/-) unit range INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant porcine factor VIII (rpFVIII) at an initial dose of 200 U/kg, with subsequent doses based on clinical measures; median total dose was 548.4 U/kg (range: 198-1803 U/kg) with a median of 3.0 infusions per patient.
Trial: 39158893
Drug: Localized nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Localized nicardipine release implants (10 implants at 4 mg each) plus standard of care
Trial: 39158894
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n=619)
Trial: 39158916
Drug: HSK16149 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 40 mg/d
Trial: 39158916
Drug: HSK16149 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 80 mg/d
Trial: 39159183
Drug: Dolutegravir (DTG)-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (DTG)-based antiretroviral therapy
Trial: 39159190
Drug: Early Occupational
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Occupational Therapy Intervention program (EOTIPS)
Trial: 39159648
Drug: Standard nab-paclitaxel-gemcitabine
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard nab-paclitaxel-gemcitabine treatment
Trial: 39159997
Drug: BEL/RTX (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEL/RTX (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous rituximab 1000 mg at weeks 4 and 6)
Trial: 39159997
Drug: BEL/PBO (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEL/PBO (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous placebo at weeks 4 and 6)
Trial: 39160109
Drug: Rapid diagnosis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid diagnosis, vaccine development and deployment, and strong funding commitment
Trial: 39160146
Drug: Bimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimodal treatment (sound therapy + electrical tongue stimulation)
Trial: 39160255
Drug: Immunotherapy targets
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy targets
Trial: 39160459
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg twice daily for at least 8 weeks, followed by 5 or 10 mg twice daily at investigator's discretion
Trial: 39160468
Drug: Tocotrienol-rich fraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocotrienol-rich fraction (TRF) vitamin E, 50 mg daily for six months
Trial: 39160566
Drug: REACH, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REACH, a web-based social learning and cognitive behavior therapy (SLCBT) intervention
Trial: 39161543
Drug: Lenalidomide 20
RxNorm normalized name: lenalidomide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 20 mg with intravenous obinutuzumab 1000 mg
Trial: 39161801
Drug: blinded i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blinded i.v. iron (1000 mg ferric derisomaltose)
Trial: 39161870
Drug: Strict bundled
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict bundled care treatment (BCT) over the first 72 hours during acute hospital care
Trial: 39161962
Drug: Varlilumab followed
RxNorm normalized name: Varlilumab
DrugBank: Varlilumab (DB11930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varlilumab followed by Atezolizumab with palliative radiation therapy (RT)
Trial: 39162035
Drug: Ketone Ester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone Ester (KE) treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily)
Trial: 39162035
Drug: Ketone Ester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone Ester (KE) treatment
Trial: 39162632
Drug: Sequential CCTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential CCTA plus CT-FFR and CT perfusion
Trial: 39162634
Drug: Lutetium 177
RxNorm normalized name: lutetium Lu 177 dotatate Injection [Lutathera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutetium 177 (specific dosage and duration not mentioned)